| Mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors E Wang, X Mi, MC Thompson, S Montoya, RQ Notti, J Afaghani, ... New England Journal of Medicine 386 (8), 735-743, 2022 | 118 | 2022 |
| Break scrub to take that phone call? A Schirmer, C Swan, SJ Hughes, T Vasilopoulos, M Oli, S Chaudhry, ... Journal of the American College of Surgeons 226 (6), 1117-1121, 2018 | 19 | 2018 |
| Presynaptic Gαo (GOA-1) signals to depress command neuron excitability and allow stretch-dependent modulation of egg laying in Caenorhabditis elegans B Ravi, J Zhao, SI Chaudhry, R Signorelli, M Bartole, RJ Kopchock 3rd, ... Genetics 218 (4), iyab080, 2021 | 15 | 2021 |
| Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t (11; 14) N Nguyen, S Chaudhry, TM Totiger, R Diaz, E Roberts, S Montoya, ... NPJ precision oncology 6 (1), 73, 2022 | 14 | 2022 |
| Identification of toxicity effects of Cu 2 O materials on C. elegans as a function of environmental ionic composition CJ Munro, MA Nguyen, C Falgons, S Chaudhry, MO Olagunju, A Bode, ... Environmental Science: Nano 7 (2), 645-655, 2020 | 8 | 2020 |
| Serotonin signals through postsynaptic Gαq, Trio RhoGEF, and diacylglycerol to promote Caenorhabditis elegans egg-laying circuit activity and behavior P Dhakal, SI Chaudhry, R Signorelli, KM Collins Genetics 221 (3), iyac084, 2022 | 6 | 2022 |
| Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia JP Brabson, T Leesang, YS Yap, J Wang, MQ Lam, B Fang, I Dolgalev, ... Cell reports 42 (1), 2023 | 5 | 2023 |
| Current state and challenges in development of targeted therapies in myelodysplastic syndromes (MDS) M Stanchina, S Chaudhry, M Karr, J Taylor Hemato 2 (2), 217-236, 2021 | 5 | 2021 |
| Protein biomarkers for response to XPO1 inhibition in haematologic malignancies TM Totiger, S Chaudhry, E Musi, J Afaghani, S Montoya, F Owusu‐Ansah, ... Journal of Cellular and Molecular Medicine 27 (4), 587-590, 2023 | 3 | 2023 |
| XPO1 overexpression is a mechanism of resistance to eprenetapopt and 5-azacitidine therapy that can be therapeutically exploited for the treatment of TP53 mutated myeloid … TL Kruer, A Quintana, M Ferrall-Fairbanks, L Zhang, H Newman, ... Blood 140 (Supplement 1), 99-100, 2022 | 2 | 2022 |
| E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial JP Bewersdorf, M Stahl, J Taylor, X Mi, NS Chandhok, J Watts, A Derkach, ... Leukemia 37 (12), 2512-2516, 2023 | 1 | 2023 |
| Vitamin C enhances PARPi efficacy for the treatment of AML JP Brabson, T Leesang, B Fang, J Wang, V Strippoli, YS Yap, ... Blood 138, 1168, 2021 | 1 | 2021 |
| Combination drug screen identifies novel epigenetic therapies to enhance menin inhibitor efficacy in KMT2A rearranged and NPM1 mutant AML TM Totiger, S Chaudhry, S Montoya, M Affer, AK Sondhi, A Chirino, ... Cancer Research 84 (6_Supplement), 3218-3218, 2024 | | 2024 |
| Abstract P26: Altered RNA Export Sensitizes to Nuclear Export Inhibition in SF3B1 Mutant MDS S Chaudhry, F Beckedorff, SS Jasdanwala, TM Totiger, M Affer, ... Blood Cancer Discovery 5 (2_Supplement), P26-P26, 2024 | | 2024 |
| Altered RNA Export in SF3B1 Mutants Increases Sensitivity to Nuclear Export Inhibition S Chaudhry, F Beckedorff, TM Totiger, M Affer, N Hariramani, S Montoya, ... Blood 142, 44, 2023 | | 2023 |
| Selinexor, Venetoclax, and Dexamethasone in t (11; 14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study) D Kazandjian, J Taylor, K Koubek, R Bukhari, M Wilson, I Schiwy, ... Blood 142, 6740, 2023 | | 2023 |
| Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells J Jahn, S Chaudhry, M Affer, A Pardo, G Pardo, J Taylor JoVE (Journal of Visualized Experiments), e64199, 2023 | | 2023 |
| Pan-cancer analysis of XPO1 R749Q mutations across 217,570 patients reveals association with high tumor mutational burden and therapy resistance TM Totiger, Y Baca, W Chiraphapphaiboon, S Chaudhry, S Montoya, ... Cancer Research 83 (7_Supplement), 4253-4253, 2023 | | 2023 |
| Abstract B018: Novel therapeutics for targeting the aberrant nuclear export machinery in colorectal cancer TM Totiger, S Chaudhry, S Montoya, M Chojnacka, G Gaidosh, J Afaghani, ... Cancer Research 82 (23_Supplement_1), B018-B018, 2022 | | 2022 |
| Abstract A04: Targeted protein degradation as a strategy to overcome non-covalent BTK inhibitor resistance in lymphoma S Montoya, E Wang, J Bourcier, S Chaudhry, T Totiger, A Pardo, G Pardo, ... Blood Cancer Discovery 3 (5_Supplement), A04-A04, 2022 | | 2022 |
